L3VLUP
ProSign in

JANX · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

JANXVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • JANX
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterJANXVRTX
Q3 2020none listed holders, n.a.31 holders, $21.9bn
Q4 2020none listed holders, n.a.30 holders, $18.4bn
Q1 2021none listed holders, n.a.31 holders, $15.4bn
Q2 20211 holders, $8.3m30 holders, $12.7bn
Q3 20211 holders, $6.5m35 holders, $10.1bn
Q4 20211 holders, $5.5m28 holders, $12.4bn
Q1 20221 holders, $4.0m23 holders, $16.1bn
Q2 20221 holders, $3.5m25 holders, $18.1bn
Q3 20221 holders, $5.4m22 holders, $18.4bn
Q4 20221 holders, $6.7m28 holders, $18.4bn
Q1 20231 holders, $1.7m26 holders, $21.4bn
Q2 20231 holders, $1.6m27 holders, $24.7bn
Q3 20231 holders, $864k33 holders, $24.3bn
Q4 2023none listed holders, n.a.32 holders, $28.6bn
Q1 20243 holders, $76m31 holders, $29.8bn
Q2 20243 holders, $98m29 holders, $33.4bn
Q3 20245 holders, $218m27 holders, $33.5bn
Q4 20248 holders, $850m26 holders, $28.5bn
Q1 20253 holders, $174m21 holders, $35.4bn
Q2 20254 holders, $182m21 holders, $32.3bn
Q3 20253 holders, $182m22 holders, $25.9bn
Q4 20252 holders, $88m26 holders, $31.8bn
Q1 20261 holders, $58m25 holders, $31.8bn
Q2 20261 holders, $1.4m26 holders, $34.6bn
JANX

Janux Therapeutics Inc

Holders
3
Reported value
$76m
Buyers
3
Sellers
0

Breadth +3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
VRTX

Vertex Pharmaceuticals Inc

Holders
31
Reported value
$29.8bn
Buyers
16
Sellers
19

Breadth -3 among 93 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q1 2024

Among the 33 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only JANX (2)

Discovery Capital Management LLC, Woodline Partners LP

Only VRTX (30)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, D. E. Shaw & Co., ExodusPoint Capital Management LP, Fidelity (FMR LLC), Invesco Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, Schonfeld Strategic Advisors LLC, T. Rowe Price Associates Inc, Tudor Investment Corp, and 5 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →